01
Cash & equivalents decreased 51.2%
Cash & equivalents changed -51.2% from the comparable as-filed period.
$88.4M→$43.2MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTKalaris Therapeutics, Inc.'s latest supported as-filed period reports revenue of $165,000. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -51.2% from the comparable as-filed period.
Net income changed -1.5% from the comparable as-filed period.
Operating income changed -1.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
KLRS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-344532SEC ↗8-KAug 11, 2026Period Aug 11, 20260001193125-26-343477SEC ↗4Aug 3, 2026Period Aug 1, 20260001193125-26-330530SEC ↗4Jul 20, 2026Period Jul 20, 20260001193125-26-309047SEC ↗8-KJul 20, 2026Period Jul 14, 20260001193125-26-308382SEC ↗8-KJul 17, 2026Period Jul 17, 20260001193125-26-306737SEC ↗8-KJul 6, 2026Period Jul 3, 20260001193125-26-296190SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 1, 2026Filed Aug 3, 2026 | KEATING LAURIEDirector | Grant Or AwardDirect | 18,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +6.8% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed +9.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-257564